Retraction of an intraperitoneal chemotherapy port: a case report and literature review
Delivery of chemotherapy directly into the peritoneal cavity is becoming part of the standard frontline management of patients with optimally cytoreduced ovarian carcinoma. Traditionally, the peritoneal access devices used for this have had relatively high complication rates including infection, blo...
Gespeichert in:
| Veröffentlicht in: | International journal of gynecological cancer 2007-09, Vol.17 (5), p.1131-1133 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1133 |
|---|---|
| container_issue | 5 |
| container_start_page | 1131 |
| container_title | International journal of gynecological cancer |
| container_volume | 17 |
| creator | Pendergrass, M. Gordinier, M.E. Parker, L.P. Metzinger, D.S. Helm, C.W. |
| description | Delivery of chemotherapy directly into the peritoneal cavity is becoming part of the standard frontline management of patients with optimally cytoreduced ovarian carcinoma. Traditionally, the peritoneal access devices used for this have had relatively high complication rates including infection, blockage, leakage, and difficulties with port access. In order to reduce the risk of infection, we have been using a Bard 9.6F silastic infusaport that does not have a Dacron cuff to secure it into the tissues of the anterior abdominal wall. It has the added advantage of being more easily removed at the end of treatment. We report a case of spontaneous retraction of such a port out of the peritoneal cavity into the subcutaneous tissues. This complication associated with a silastic cuffless port is presented to raise awareness of this possible complication and suggest ways of preventing it. |
| doi_str_mv | 10.1111/j.1525-1438.2007.00910.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2552824681</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1048891X24040349</els_id><sourcerecordid>2552824681</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4987-3b5f1c97d4bba3ea6858c9385e1b9a81d73cd06885782600662f63b90023beb53</originalsourceid><addsrcrecordid>eNqNkNuKFDEQhoMo7kFfQQJe95hDp5MWb3TR3ZUFQRS9C-l0NZOxpzMm6Z2dt7faGfRSAyGVyv9XVT5CKGcrjuvVZsWVUBWvpVkJxvSKsRbfHh6R8z8PjzFmtalMy7-fkYucNwxVgrVPyRnX0jSsrs_Jt89QkvMlxInGgbqJhgkTO0ihxAncSP0atrGsAZMHuoupvKaOepeBJliu6OnpGAoKypyW7H2A_TPyZHBjhuen85J8_fD-y9VNdffp-vbq7V3l69boSnZq4L7Vfd11ToJrjDK-lUYB71pneK-l71ljjNJGNIw1jRga2bWMCdlBp-QleXmsu0vx5wy52E2c04QtrVBKGFE3hqPKHFU-xZwTDHaXwtalg-XMLkTtxi7g7ALOLkTtb6L2Aa0vTg3mbgv9X-MJIQrqo2AfR4SQf4zzHpJdI7uyxjJYSGldLUUZzs0q3EKj7c3JFkY4_Pc89vbjNQZof3e0A8JF4MlmH2Dy0IcEvtg-hn__7RfIx6jJ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2552824681</pqid></control><display><type>article</type><title>Retraction of an intraperitoneal chemotherapy port: a case report and literature review</title><source>MEDLINE</source><source>Wiley Online Library Journals</source><creator>Pendergrass, M. ; Gordinier, M.E. ; Parker, L.P. ; Metzinger, D.S. ; Helm, C.W.</creator><creatorcontrib>Pendergrass, M. ; Gordinier, M.E. ; Parker, L.P. ; Metzinger, D.S. ; Helm, C.W.</creatorcontrib><description>Delivery of chemotherapy directly into the peritoneal cavity is becoming part of the standard frontline management of patients with optimally cytoreduced ovarian carcinoma. Traditionally, the peritoneal access devices used for this have had relatively high complication rates including infection, blockage, leakage, and difficulties with port access. In order to reduce the risk of infection, we have been using a Bard 9.6F silastic infusaport that does not have a Dacron cuff to secure it into the tissues of the anterior abdominal wall. It has the added advantage of being more easily removed at the end of treatment. We report a case of spontaneous retraction of such a port out of the peritoneal cavity into the subcutaneous tissues. This complication associated with a silastic cuffless port is presented to raise awareness of this possible complication and suggest ways of preventing it.</description><identifier>ISSN: 1048-891X</identifier><identifier>EISSN: 1525-1438</identifier><identifier>DOI: 10.1111/j.1525-1438.2007.00910.x</identifier><identifier>PMID: 17386044</identifier><language>eng</language><publisher>Malden, USA: Elsevier Inc</publisher><subject>Antineoplastic Agents - administration & dosage ; Carcinoma - drug therapy ; Carcinoma - surgery ; Case reports ; Catheterization - adverse effects ; Chemotherapy ; Drug Delivery Systems - adverse effects ; Female ; Humans ; Infusions, Parenteral - adverse effects ; intraperitoneal chemotherapy ; Middle Aged ; Ovarian cancer ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - surgery ; peritoneal access device ; Peritoneal Cavity</subject><ispartof>International journal of gynecological cancer, 2007-09, Vol.17 (5), p.1131-1133</ispartof><rights>2007 Blackwell Science Ltd.</rights><rights>2007, IGCS and ESGO</rights><rights>Copyright © 2007 Blackwell Publishing Ltd.</rights><rights>Copyright © 2007 Blackwell Publishing Ltd.2007</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4987-3b5f1c97d4bba3ea6858c9385e1b9a81d73cd06885782600662f63b90023beb53</citedby><cites>FETCH-LOGICAL-c4987-3b5f1c97d4bba3ea6858c9385e1b9a81d73cd06885782600662f63b90023beb53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1525-1438.2007.00910.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1525-1438.2007.00910.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17386044$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pendergrass, M.</creatorcontrib><creatorcontrib>Gordinier, M.E.</creatorcontrib><creatorcontrib>Parker, L.P.</creatorcontrib><creatorcontrib>Metzinger, D.S.</creatorcontrib><creatorcontrib>Helm, C.W.</creatorcontrib><title>Retraction of an intraperitoneal chemotherapy port: a case report and literature review</title><title>International journal of gynecological cancer</title><addtitle>Int J Gynecol Cancer</addtitle><description>Delivery of chemotherapy directly into the peritoneal cavity is becoming part of the standard frontline management of patients with optimally cytoreduced ovarian carcinoma. Traditionally, the peritoneal access devices used for this have had relatively high complication rates including infection, blockage, leakage, and difficulties with port access. In order to reduce the risk of infection, we have been using a Bard 9.6F silastic infusaport that does not have a Dacron cuff to secure it into the tissues of the anterior abdominal wall. It has the added advantage of being more easily removed at the end of treatment. We report a case of spontaneous retraction of such a port out of the peritoneal cavity into the subcutaneous tissues. This complication associated with a silastic cuffless port is presented to raise awareness of this possible complication and suggest ways of preventing it.</description><subject>Antineoplastic Agents - administration & dosage</subject><subject>Carcinoma - drug therapy</subject><subject>Carcinoma - surgery</subject><subject>Case reports</subject><subject>Catheterization - adverse effects</subject><subject>Chemotherapy</subject><subject>Drug Delivery Systems - adverse effects</subject><subject>Female</subject><subject>Humans</subject><subject>Infusions, Parenteral - adverse effects</subject><subject>intraperitoneal chemotherapy</subject><subject>Middle Aged</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Ovarian Neoplasms - surgery</subject><subject>peritoneal access device</subject><subject>Peritoneal Cavity</subject><issn>1048-891X</issn><issn>1525-1438</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqNkNuKFDEQhoMo7kFfQQJe95hDp5MWb3TR3ZUFQRS9C-l0NZOxpzMm6Z2dt7faGfRSAyGVyv9XVT5CKGcrjuvVZsWVUBWvpVkJxvSKsRbfHh6R8z8PjzFmtalMy7-fkYucNwxVgrVPyRnX0jSsrs_Jt89QkvMlxInGgbqJhgkTO0ihxAncSP0atrGsAZMHuoupvKaOepeBJliu6OnpGAoKypyW7H2A_TPyZHBjhuen85J8_fD-y9VNdffp-vbq7V3l69boSnZq4L7Vfd11ToJrjDK-lUYB71pneK-l71ljjNJGNIw1jRga2bWMCdlBp-QleXmsu0vx5wy52E2c04QtrVBKGFE3hqPKHFU-xZwTDHaXwtalg-XMLkTtxi7g7ALOLkTtb6L2Aa0vTg3mbgv9X-MJIQrqo2AfR4SQf4zzHpJdI7uyxjJYSGldLUUZzs0q3EKj7c3JFkY4_Pc89vbjNQZof3e0A8JF4MlmH2Dy0IcEvtg-hn__7RfIx6jJ</recordid><startdate>200709</startdate><enddate>200709</enddate><creator>Pendergrass, M.</creator><creator>Gordinier, M.E.</creator><creator>Parker, L.P.</creator><creator>Metzinger, D.S.</creator><creator>Helm, C.W.</creator><general>Elsevier Inc</general><general>Blackwell Publishing Inc</general><general>Copyright Blackwell Publishing Ltd</general><general>BMJ Publishing Group LTD</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>200709</creationdate><title>Retraction of an intraperitoneal chemotherapy port: a case report and literature review</title><author>Pendergrass, M. ; Gordinier, M.E. ; Parker, L.P. ; Metzinger, D.S. ; Helm, C.W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4987-3b5f1c97d4bba3ea6858c9385e1b9a81d73cd06885782600662f63b90023beb53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Antineoplastic Agents - administration & dosage</topic><topic>Carcinoma - drug therapy</topic><topic>Carcinoma - surgery</topic><topic>Case reports</topic><topic>Catheterization - adverse effects</topic><topic>Chemotherapy</topic><topic>Drug Delivery Systems - adverse effects</topic><topic>Female</topic><topic>Humans</topic><topic>Infusions, Parenteral - adverse effects</topic><topic>intraperitoneal chemotherapy</topic><topic>Middle Aged</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Ovarian Neoplasms - surgery</topic><topic>peritoneal access device</topic><topic>Peritoneal Cavity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pendergrass, M.</creatorcontrib><creatorcontrib>Gordinier, M.E.</creatorcontrib><creatorcontrib>Parker, L.P.</creatorcontrib><creatorcontrib>Metzinger, D.S.</creatorcontrib><creatorcontrib>Helm, C.W.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>International journal of gynecological cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pendergrass, M.</au><au>Gordinier, M.E.</au><au>Parker, L.P.</au><au>Metzinger, D.S.</au><au>Helm, C.W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Retraction of an intraperitoneal chemotherapy port: a case report and literature review</atitle><jtitle>International journal of gynecological cancer</jtitle><addtitle>Int J Gynecol Cancer</addtitle><date>2007-09</date><risdate>2007</risdate><volume>17</volume><issue>5</issue><spage>1131</spage><epage>1133</epage><pages>1131-1133</pages><issn>1048-891X</issn><eissn>1525-1438</eissn><abstract>Delivery of chemotherapy directly into the peritoneal cavity is becoming part of the standard frontline management of patients with optimally cytoreduced ovarian carcinoma. Traditionally, the peritoneal access devices used for this have had relatively high complication rates including infection, blockage, leakage, and difficulties with port access. In order to reduce the risk of infection, we have been using a Bard 9.6F silastic infusaport that does not have a Dacron cuff to secure it into the tissues of the anterior abdominal wall. It has the added advantage of being more easily removed at the end of treatment. We report a case of spontaneous retraction of such a port out of the peritoneal cavity into the subcutaneous tissues. This complication associated with a silastic cuffless port is presented to raise awareness of this possible complication and suggest ways of preventing it.</abstract><cop>Malden, USA</cop><pub>Elsevier Inc</pub><pmid>17386044</pmid><doi>10.1111/j.1525-1438.2007.00910.x</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1048-891X |
| ispartof | International journal of gynecological cancer, 2007-09, Vol.17 (5), p.1131-1133 |
| issn | 1048-891X 1525-1438 |
| language | eng |
| recordid | cdi_proquest_journals_2552824681 |
| source | MEDLINE; Wiley Online Library Journals |
| subjects | Antineoplastic Agents - administration & dosage Carcinoma - drug therapy Carcinoma - surgery Case reports Catheterization - adverse effects Chemotherapy Drug Delivery Systems - adverse effects Female Humans Infusions, Parenteral - adverse effects intraperitoneal chemotherapy Middle Aged Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - surgery peritoneal access device Peritoneal Cavity |
| title | Retraction of an intraperitoneal chemotherapy port: a case report and literature review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T14%3A29%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Retraction%20of%20an%20intraperitoneal%20chemotherapy%20port:%20a%20case%20report%20and%20literature%20review&rft.jtitle=International%20journal%20of%20gynecological%20cancer&rft.au=Pendergrass,%20M.&rft.date=2007-09&rft.volume=17&rft.issue=5&rft.spage=1131&rft.epage=1133&rft.pages=1131-1133&rft.issn=1048-891X&rft.eissn=1525-1438&rft_id=info:doi/10.1111/j.1525-1438.2007.00910.x&rft_dat=%3Cproquest_cross%3E2552824681%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2552824681&rft_id=info:pmid/17386044&rft_els_id=S1048891X24040349&rfr_iscdi=true |